Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

31.38 -0.59 (-1.86%)
Streaming Delayed Price Updated: 1:51 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zenas BioPharma, Inc. - Common Stock

News headline image
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. ↗
This clinical-stage biotech focused on immunology therapies reported a notable insider buy amid a year of strong stock performance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
Why Is ZBIO Stock Falling Pre-Market Today? ↗
Via Stocktwits
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
Via MarketBeat
News headline image
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug ↗
Zenas BioPharma secures global rights to orelabrutinib in multiple sclerosis, expands autoimmune pipeline, and raises $120 million in private placement. 
Via Benzinga
News headline image
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress ↗
Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026. 
Via Benzinga
News headline image
Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday ↗
 
Via Benzinga
News headline image
Visa To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
StandardAero Surges In Market Debut ↗
Shares of StandardAero jumped 36% in the company's trading debut as the aircraft maintenance services provider raised $1.44 billion in its IPO. Additionally, Chain Bridge Bancorp opened on Oct. 5 at... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Week In Review: Zenas Raises $259 Million In IPO ↗
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Trio Of Biotech IPOs Climb In Debut ↗
A trio of biotech companies' shares rose on Friday in their first trading sessions. Bicara Therapeutics, MBX Biosciences, and Zenas BioPharma each sold more shares in their respective initial public... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.